Skip to content

Study · Non-randomized trial · 1991

4 results

Vasoactive intestinal polypeptide loses its ability to increase vaginal blood flow after menopause.

Palle C, Bredkjaer HE, Fahrenkrug J, Ottesen B

American journal of obstetrics and gynecology1 Feb 1991Cited by 19 (Europe PMC)

PMID1992701 (opens in a new tab)DOI10.1016/s0002-9378(11)80019-0 (opens in a new tab)PepBankPUB-01992701
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women receiving hormone replacement therapy, the vasodilatory response of vaginal blood flow to VIP was identical to that of young women.

    In plain wordsIn postmenopausal women on hormone replacement therapy, VIP raised vaginal blood flow as much as in young women.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVaginal blood flow response to VIP in women on hormone replacement therapy
    Study

    n: not reported in source

    Comparator
    Young women
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In women who were receiving hormonal replacement therapy the vasodilatory response induced by vasoactive intestinal polypeptide was identical to that of young women
    1 context sentence
    Summary · context
    The effect of vasoactive intestinal polypeptide on vaginal blood flow was investigated in postmenopausal women.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women receiving no hormone replacement therapy, VIP produced no vasodilatory response of vaginal blood flow.

    In plain wordsIn postmenopausal women not on hormone replacement therapy, VIP did not raise vaginal blood flow.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVaginal blood flow response to VIP in women without replacement therapy
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas in postmenopausal women who were receiving no replacement therapy, the response induced by vasoactive intestinal polypeptide was absent
    1 context sentence
    Summary · context
    The effect of vasoactive intestinal polypeptide on vaginal blood flow was investigated in postmenopausal women.
  3. 03HumanNon-randomized trialPharmacokinetics

    Plasma VIP levels were identical in postmenopausal women with and without hormone replacement therapy.

    In plain wordsBlood VIP levels were the same in postmenopausal women with and without hormone replacement therapy.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma VIP levels
    Study

    n: not reported in source

    Comparator
    Postmenopausal women without hormone replacement therapy
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma levels of vasoactive intestinal polypeptide and systemic cardiovascular effects were identical in the two groups.
    1 context sentence
    Summary · context
    The effect of vasoactive intestinal polypeptide on vaginal blood flow was investigated in postmenopausal women.
  4. 04HumanNon-randomized trialSafety outcome

    Systemic cardiovascular effects of VIP were identical in postmenopausal women with and without hormone replacement therapy.

    In plain wordsVIP had the same effects on the circulation in postmenopausal women with and without hormone replacement therapy.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSystemic cardiovascular effects of VIP
    Study

    n: not reported in source

    Comparator
    Postmenopausal women without hormone replacement therapy
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma levels of vasoactive intestinal polypeptide and systemic cardiovascular effects were identical in the two groups.
    1 context sentence
    Summary · context
    The effect of vasoactive intestinal polypeptide on vaginal blood flow was investigated in postmenopausal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.